News Center



Home News Center News

Opportunities and Challenges for Pharma Companies in the AI Era

Oct 18-2024   



With the application of AI technology in the pharmaceutical industry as the core, this event aims to explore the deep integration of AI and the medical industry through exchanges with Tencent.

 

Zhang Yang, Director of Business Development, Tencent Health: Technology and connectivity - helping pharmaceutical companies upgrade their industry

Director Zhang Yang introduced the history of Tencent's development, emphasising its adherence to the concepts of user-centricity and technology for good. Tencent is committed to promoting sustainable social value innovation, focusing on the CSIG of the industrial internet, and supporting the digital transformation of various industries through the integration of technological resources, especially in the field of healthcare. He showed that Tencent has achieved remarkable results by using AI, big data and other advanced technologies, such as developing medical models and digital people and applying them to different scenarios, and promoting the digital upgrading of the healthcare industry through technological innovation and ecological cooperation.

 

Chen Tao, Alumni Representative and General Manager of Shiyao Group: Strategy and innovation of pharmaceutical companies in the era of AI

Alumnus Chen Tao shared his experience of 'one man's global enterprise', demonstrating the use of the internet and AI technology to achieve cross-regional collaboration and development, and using case studies to illustrate the dramatic changes brought about by network communication and collaboration, i.e. the availability of expert support, resources and inspiration from around the world in the age of AI. Chen Tao discussed the potential of AI in the healthcare industry, particularly in drug discovery, diagnostic accuracy and personalised treatments, to improve R&D efficiency, reduce costs and bring about disruptive innovation. He concluded by highlighting the huge potential of AI in drug discovery and development, and expressed his optimism for the future of the AI pharma sector as a great era full of opportunities.

 

Chen Yonghe, Senior Architect, Tencent Health: AI leads innovation drive to build a new ecosystem of pharmaceutical digital intelligence

Chen Yonghe introduced Tencent's progress in artificial intelligence, especially AI big models, and its application in the medical field. Tencent has developed a big model focused on medical scenarios, which is both versatile and professional, and can handle complex professional medical tasks. He showed the specific application scenarios and highlighted its role in improving the effectiveness of medical services. From the technical details, Tencent optimised the training framework and inference engine to achieve high performance and low cost, and integrated a large amount of authoritative medical data knowledge to ensure the accuracy and practicality of the model. Finally, Chen Yonghe touched on the future trends of AI, including improving the efficiency of content creation and the assistive role in daily work, showing how AI technology is being integrated into the daily life and work of pharmaceutical companies.

 

Hou Hong, Assistant Professor, NSD, Peking University and PhD, University of Cambridge: Value creation principles of AI technology and competitive advantages of enterprises

Combining AI technology and business strategy, Prof. Hou Hong focused on the roles and interrelationships of big models and intelligences in the field of AI, and put forward key ideas, including thoughts on the future development trend of AI, especially the relationship between big models, intelligences and humans in the future. Prof. Hou Hong pointed out that the concept of "agent" is less mentioned in the current discussion, and there is a difference between big models and intelligences. Big models focus on prediction, while intelligences are able to do complex task decomposition and cross-model collaboration, and there is still a black box problem in big models, while intelligences are able to solve complex problems by task decomposition and invoking the capabilities of different models.Big models still have black-box problems, while intelligences are able to solve complex problems through task decomposition and the ability to invoke different models, which requires human involvement in workflow design.Mr Hou suggested that companies should view big models and intelligences as complementary, and emphasised the role of both in achieving general purpose artificial intelligence (AGI).

Finally, he referred to brain research from a biological perspective, comparing intelligences and macromodels to different parts of the brain corresponding to the functions of intuitive decision-making and rational analysis, respectively.

Opportunities and Challenges for Pharma Companies in the AI Era

Oct 18-2024   



With the application of AI technology in the pharmaceutical industry as the core, this event aims to explore the deep integration of AI and the medical industry through exchanges with Tencent.

 

Zhang Yang, Director of Business Development, Tencent Health: Technology and connectivity - helping pharmaceutical companies upgrade their industry

Director Zhang Yang introduced the history of Tencent's development, emphasising its adherence to the concepts of user-centricity and technology for good. Tencent is committed to promoting sustainable social value innovation, focusing on the CSIG of the industrial internet, and supporting the digital transformation of various industries through the integration of technological resources, especially in the field of healthcare. He showed that Tencent has achieved remarkable results by using AI, big data and other advanced technologies, such as developing medical models and digital people and applying them to different scenarios, and promoting the digital upgrading of the healthcare industry through technological innovation and ecological cooperation.

 

Chen Tao, Alumni Representative and General Manager of Shiyao Group: Strategy and innovation of pharmaceutical companies in the era of AI

Alumnus Chen Tao shared his experience of 'one man's global enterprise', demonstrating the use of the internet and AI technology to achieve cross-regional collaboration and development, and using case studies to illustrate the dramatic changes brought about by network communication and collaboration, i.e. the availability of expert support, resources and inspiration from around the world in the age of AI. Chen Tao discussed the potential of AI in the healthcare industry, particularly in drug discovery, diagnostic accuracy and personalised treatments, to improve R&D efficiency, reduce costs and bring about disruptive innovation. He concluded by highlighting the huge potential of AI in drug discovery and development, and expressed his optimism for the future of the AI pharma sector as a great era full of opportunities.

 

Chen Yonghe, Senior Architect, Tencent Health: AI leads innovation drive to build a new ecosystem of pharmaceutical digital intelligence

Chen Yonghe introduced Tencent's progress in artificial intelligence, especially AI big models, and its application in the medical field. Tencent has developed a big model focused on medical scenarios, which is both versatile and professional, and can handle complex professional medical tasks. He showed the specific application scenarios and highlighted its role in improving the effectiveness of medical services. From the technical details, Tencent optimised the training framework and inference engine to achieve high performance and low cost, and integrated a large amount of authoritative medical data knowledge to ensure the accuracy and practicality of the model. Finally, Chen Yonghe touched on the future trends of AI, including improving the efficiency of content creation and the assistive role in daily work, showing how AI technology is being integrated into the daily life and work of pharmaceutical companies.

 

Hou Hong, Assistant Professor, NSD, Peking University and PhD, University of Cambridge: Value creation principles of AI technology and competitive advantages of enterprises

Combining AI technology and business strategy, Prof. Hou Hong focused on the roles and interrelationships of big models and intelligences in the field of AI, and put forward key ideas, including thoughts on the future development trend of AI, especially the relationship between big models, intelligences and humans in the future. Prof. Hou Hong pointed out that the concept of "agent" is less mentioned in the current discussion, and there is a difference between big models and intelligences. Big models focus on prediction, while intelligences are able to do complex task decomposition and cross-model collaboration, and there is still a black box problem in big models, while intelligences are able to solve complex problems by task decomposition and invoking the capabilities of different models.Big models still have black-box problems, while intelligences are able to solve complex problems through task decomposition and the ability to invoke different models, which requires human involvement in workflow design.Mr Hou suggested that companies should view big models and intelligences as complementary, and emphasised the role of both in achieving general purpose artificial intelligence (AGI).

Finally, he referred to brain research from a biological perspective, comparing intelligences and macromodels to different parts of the brain corresponding to the functions of intuitive decision-making and rational analysis, respectively.